Literature DB >> 16950786

Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity.

Hester A Doyle1, Jing Zhou, Martin J Wolff, Bohdan P Harvey, Robert M Roman, Renelle J Gee, Raymond A Koski, Mark J Mamula.   

Abstract

A hallmark of the immune system is the ability to ignore self-antigens. In attempts to bypass normal immune tolerance, a post-translational protein modification was introduced into self-antigens to break T and B cell tolerance. We demonstrate that immune tolerance is bypassed by immunization with a post-translationally modified melanoma antigen. In particular, the conversion of an aspartic acid to an isoaspartic acid within the melanoma antigen tyrosinase-related protein (TRP)-2 peptide-(181-188) makes the otherwise immunologically ignored TRP-2 antigen immunogenic. Tetramer analysis of iso-Asp TRP-2 peptide-immunized mice demonstrated that CD8+ T cells not only recognized the isoaspartyl TRP-2 peptide but also the native TRP-2 peptide. These CD8+ T cells functioned as cytotoxic T lymphocytes, as they effectively lysed TRP-2 peptide-pulsed targets both in vitro and in vivo. Potentially, post-translational protein modification can be utilized to trigger strong immune responses to either tumor proteins or potentially weakly immunogenic pathogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950786     DOI: 10.1074/jbc.M604847200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 2.  Autoantigens in systemic autoimmunity: critical partner in pathogenesis.

Authors:  A Rosen; L Casciola-Rosen
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

Review 3.  Post-translationally modified T cell epitopes: immune recognition and immunotherapy.

Authors:  Jan Petersen; Anthony W Purcell; Jamie Rossjohn
Journal:  J Mol Med (Berl)       Date:  2009-09-08       Impact factor: 4.599

4.  Non-repair pathways for minimizing protein isoaspartyl damage in the yeast Saccharomyces cerevisiae.

Authors:  Alexander N Patananan; Joseph Capri; Julian P Whitelegge; Steven G Clarke
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

Review 5.  Transmethylation in immunity and autoimmunity.

Authors:  Brian R Lawson; Theodoros Eleftheriadis; Virginie Tardif; Rosana Gonzalez-Quintial; Roberto Baccala; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2011-12-24       Impact factor: 3.969

6.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

7.  Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.

Authors:  Hester A Doyle; Raymond A Koski; Nathalie Bonafé; Ross A Bruck; Stephanie M Tagliatela; Renelle J Gee; Mark J Mamula
Journal:  Cancer Immunol Immunother       Date:  2018-07-28       Impact factor: 6.968

8.  Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Authors:  Timothy M Clay; Takuya Osada; Zachary C Hartman; Amy Hobeika; Gayathri Devi; Michael A Morse; H Kim Lyerly
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 9.  Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Authors:  Matthew M Gubin; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

10.  Autoimmunity to isomerized histone H2B in systemic lupus erythematosus.

Authors:  Hester A Doyle; Dana W Aswad; Mark J Mamula
Journal:  Autoimmunity       Date:  2012-12-03       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.